A new study published online in the Journal of Leukocyte Biology suggests a new approach to treating patients with sepsis, one of the most frequent causes of morbidity and mortality in intensive care units (ICUs). Specifically, the report reveals that in the late stage of sepsis, HMGB1, or the "high mobility group box 1" protein, might be a target for future therapies because the protein plays a key role in the development of post-sepsis immunosuppression and sepsis-induced dysfunction of neutrophils (white blood cells).
"Therapeutic interventions for sepsis are limited to the use of antibiotics and fluid resuscitation, since specific pharmacological treatment is not available to prevent or correct sepsis-induced immunosuppression," said Jean-Marc Tadié, M.D., Ph.D., a researcher involved in the work from the Department of Infectious Diseases and Medical Intensive Care Unit at the Pontchaillou University Hospital, Rennes, France. "Targeting molecules such as HMGB1 represents a new therapeutic approach that could help people recover from septic shock."
To make their discovery, Tadié and colleagues first used a murine model of polymicrobial septic peritonitis with fluid resuscitation and antibiotic administration, mirroring standard care for humans. Using this model, they studied the late consequences of infection on neutrophils and the implication of HMGB1. In a second set of experiments, ex-vivo experiments were carried out to study the role of HMGB1 in neutrophil dysfunction in patients admitted to the ICU for septic shock. The researchers found that after sepsis, the ability of neutrophils to kill bacteria was diminished. They also found that HMGB1 was significantly increased in the late phase of sepsis. To establish the importance of HMGB1 in regulating sepsis-mediated neutrophil dysfunction, they demonstrated that neutralizing HMGB1 restored the neutrophils' ability to kill bacteria after septic shock.
"There is increasing evidence of immune paralysis or dysfunction in sepsis particularly in the 'adaptive' immune system," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "The identification of a pathway that can rejuvenate neutrophil function is a major step forward because these cells of the 'innate' immune system can act much faster, a critical issue in sepsis"
The Journal of Leukocyte Biology publishes peer-reviewed manuscripts on original investigations focusing on the cellular and molecular biology of leukocytes and on the origins, the developmental biology, biochemistry and functions of granulocytes, lymphocytes, mononuclear phagocytes and other cells involved in host defense and inflammation. The Journal of Leukocyte Biology is published by the Society for Leukocyte Biology.
Details: Caroline Piau, Nathaniel Bone, Yves Le Tulzo, Edward Abraham, Karin Tarte, and Jaroslaw W. Zmijewski. Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J. Leukoc. Biol. June 2017 101:1281-1287; doi:10.1189/jlb.5HI0316-128RR ; http://www.jleukbio.org/content/101/6/1281.abstract
Journal of Leukocyte Biology